Background {#Sec1}
==========

Postmenopausal osteoporosis (PMOP) is a common metabolic bone disorder characterized by low bone mineral density (BMD) and increased fracture risks \[[@CR1]--[@CR3]\]. It is estimated that osteoporosis affects approximately 10 million American adults, with another 34 million being at high risk due to low bone mass \[[@CR4]\].

The pathophysiology of PMOP is considered as a disorder or negative imbalance of bone metabolism and remodeling, with bone resorption outpacing bone formation \[[@CR3]\], suggesting that vitamin D and parathyroid hormone (PTH) and other factors related to bone resorption and formation may play a key role in the underlying mechanism and pathophysiology of PMOP \[[@CR5]--[@CR8]\]. Furthermore, genetic factors including genes and gene polymorphisms may also play an important role in the development of PMOP \[[@CR9]\].

Estrogen is another important hormone that plays an important role in the pathogenesis of PMOP, knowing that reduced ovarian production of estrogen after menopause is a cause for the initial phase of rapid bone loss and osteoporosis in women \[[@CR3]\]. Estrogen is known as an important regulator of bone metabolism, and estrogen deficiency is believed to be the cause of BMD loss, increased mechanical loading-induced bone remodeling, and the development of PMOP \[[@CR10]\]. Knowing that the action of estrogen is predominantly mediated by estrogen receptor (ER), including ERα and ERβ by binding to different ligands to mediate various biological effects \[[@CR3], [@CR10]\], more attention has been paid to the relationship between ERs and PMOP risk and BMD in postmenopausal women \[[@CR11]--[@CR38]\]. However, the results of studies currently available about this issue are controversial.

Previous meta-analyses have been performed to assess the pooled effects of ER gene polymorphisms on BMD and fracture risk \[[@CR39]--[@CR41]\]. WANG et al. \[[@CR39]\] showed that the ERα *Xba*I (rs9340799) polymorphism was associated with BMD at diverse skeletal sites, and ERα *Pvu*II (rs2234693) PP genotype played a role in protecting the lumbar spine but on the other hand might be a risk factor for the femoral neck fracture. However, to the best of our knowledge, no meta-analysis has been performed to explore the relationships between ER gene \[ERα *Xba*I (rs9340799), ERα *Pvu*II (rs2234693) and ERα G2014A (rs2228480)\] and ERβ gene \[ERβ *Alu*I (rs4986938) and ERβ *Rsa*I (rs1256049)\] polymorphisms and PMOP susceptibility and BMD of the lumbar spine and femoral neck in postmenopausal women. To address these issues, we performed a meta-analysis of all currently available studies relating ER gene \[ERα *Xba*I (rs9340799), ERα *Pvu*II (rs2234693) and ERα G2014A (rs2228480)\] and ERβ gene \[ERβ *Alu*I (rs4986938) and ERβ *Rsa*I (rs1256049)\] polymorphisms with PMOP risk and BMD.

Methods {#Sec2}
=======

Data sources and searches {#Sec3}
-------------------------

We searched PubMed, EMBASE, Web of Science, the Cochrane Library and China WeiPu Library to identify case-control studies that investigated the associations between ERα gene polymorphisms \[ERα *Xba*I (rs9340799), ERα *Pvu*II (rs2234693) and ERα G2014A (rs2228480)\] ERβ gene polymorphisms \[ERβ *Alu*I (rs4986938) and ERβ *Rsa*I (rs1256049)\] and osteoporosis susceptibility and BMD in postmenopausal women by using the following search terms ('PMOP' OR 'Postmenopausal osteoporosis' OR 'Postmenopausal') AND ('Estrogen Receptor' OR 'ER') AND ('polymorphism' OR 'single nucleotide polymorphism' OR 'SNP' OR 'variation'). To analyze the pooled effects of ER gene polymorphisms on BMD, the following search terms were used: ('PMOP' OR 'Postmenopausal osteoporosis' OR 'Postmenopausal') AND ('Estrogen Receptor' OR 'ER') AND ('polymorphism' OR 'single nucleotide polymorphism' OR 'SNP' OR 'variation') AND ('BMD' OR 'bone mineral density'). Then, one-by-one screening was performed by two authors according to the inclusion and exclusion criteria. No language restrictions were applied. Secondary searches of eligible studies were conducted by searching the reference lists of the selected studies, reviews or comments.

Inclusion and exclusion criteria {#Sec4}
--------------------------------

The inclusion criteria of our meta-analysis are as follows: (1) case-control studies; (2) studies on BMD and fracture risks in postmenopausal women with PMOP due to estrogen deficiency using postmenopausal women without PMOP or healthy volunteers as control; (3) studies reporting alleles and genotypes of at least one of the ER gene polymorphisms in women with or without PMOP: ERα *Xba*I (rs9340799), ERα *Pvu*II (rs2234693), ERα G2014A (rs2228480), ERβ *Alu*I (rs4986938) and ERβ *Rsa*I (rs1256049); (3) studies reporting the sample size, mean and standard deviation (SD) of BMD (g/cm^2^) or BMD Z value in PMOP women with at least one of the ER genotypes; and (4) studies with sufficient data. The exclusion criteria were: (1) reviews or case reports without controls, and (2) studies with no availability of current data; and (3) duplicated reports.

Data extraction {#Sec5}
---------------

Data from the eligible studies were extracted according to the inclusion and exclusion criteria by two authors, and a consensus was reached by discussion. In the study of associations between ER gene polymorphisms and PMOP risk, the following data were collected: author list, year of publication, ethnicity, sample size, alleles, genotype of each gene polymorphism and Hardy-Weinberg equilibrium (HWE). The following data were collected for analysis of differences in BMD in PMOP women with various ER genotypes: author list, year of publication, ethnicity, the number of cases and mean and SD of BMD (g/cm^2^) and BMD Z value.

Data synthesis and statistical analysis {#Sec6}
---------------------------------------

We calculated odds ratios (OR) and 95% confidence interval (CI) to evaluate the association between ER gene polymorphisms and PMOP risk (osteoporosis occurred in postmenopausal women due to estrogen deficiency as represented by low BMD and increased fracture risks). The strength of association between ER gene polymorphisms and PMOP susceptibility was evaluated by OR and 95% CI under the allele contrast model, heterozygote model, homozygote model, dominant model and recessive model. HWE was calculated in the control population to evaluate the quality of the data by using chisquare test. Regarding the associations between BMD and ER gene polymorphisms, we compared BMD (g/cm^2^) and BMD Z value in PMOP women under the heterozygote and homozygote model respectively using the weight mean difference (WMD) and 95% CI. Heterogeneity of the included studies was examined by a chi-squared-based Q statistical test and quantified by I2 metric value. If I2 value was \> 50% or *P* \< 0.10, ORs and WMD were pooled by the random effect model; otherwise, the fixed effect model was used. Power analysis was performed using the Power and Precision V4 software (Biostat Inc., Englewood, USA). Sensitivity analysis was performed to assess the impact of each study on the combined effect of the present meta-analysis. Besides, subgroup analysis was also performed according to the ethnicity of the study populations. Stata 12.0 software (StataCorp, College Station, TX, USA) was used and a *P \<* 0.05 was considered as statistically significant.

Results {#Sec7}
=======

Study selection and characteristics {#Sec8}
-----------------------------------

A total of 28 studies \[[@CR11]--[@CR38]\] were finally recruited in our meta-analysis. The study selection and inclusion process is shown in Fig. [1](#Fig1){ref-type="fig"}. Fourteen studies \[[@CR11]--[@CR24]\] reported the association between ERα *Xba*I and PMOP risk, and the number of the included studies that reported the alleles and genotypes of ERα *Pvu*II, ERα G2014A, ERβ *Alu*I and ERβ *Rsa*I was 16 \[[@CR11]--[@CR25], [@CR32]\], 4 \[[@CR26]--[@CR29]\], 4 \[[@CR17], [@CR30]--[@CR32]\] and 2 \[[@CR30], [@CR31]\], respectively. Ivanova et al. \[[@CR20]\], Albagha et al. \[[@CR33]\], Aerssens et al. \[[@CR24]\], Kurt et al. \[[@CR34]\], Ge et al. \[[@CR36]\] and Pérez et al. \[[@CR19]\] reported both the lumbar spine and femoral neck BMD (g/cm^2^). Jeedigunta et al. \[[@CR15]\] and Kurabayashi et al. \[[@CR35]\] were also recruited in the assessment of the lumbar spine BMD (g/cm^2^) in ERα *Xba*I genotypes. Ivanova et al. \[[@CR20]\], Albagha et al. \[[@CR33]\] and An et al. \[[@CR38]\] reported both the lumbar spine and femoral neck Z values. Shang et al. \[[@CR11]\] also studied the lumbar spine Z value in PMOP with ERα *Xba*I genotypes. Ten studies \[[@CR15], [@CR19], [@CR20], [@CR23], [@CR24], [@CR33]--[@CR37]\] and 8 studies \[[@CR19], [@CR20], [@CR23], [@CR24], [@CR33], [@CR34], [@CR36], [@CR37]\] were recruited in the pooled analysis of differences in lumbar spine and femoral neck BMD (g/cm^2^) in PMOP women carrying ERα *Pvu*II, respectively. With regard to differences in lumbar spine and femoral neck Z value in PMOP women with ERα *Pvu*II, 4 studies \[[@CR11], [@CR20], [@CR33], [@CR38]\] and 3 studies \[[@CR20], [@CR33], [@CR38]\] were included in our meta-analysis, respectively. In addition, all these studies complied with HWE. The characteristics of the included studies are shown in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"}.Fig. 1Flow chart showing the process of selectionTable 1General characteristics of studies assciated with postmenopausal osteoporosis riskAuthorYearEthnicitySample SizeERα *Xba*IHWECaseControlCaseControlXxXXXxxxXxXXXxxxShang et al.2016Asian1982763385814646610944310891770.77Wang et al.2015Asian727212519551521321262820.21Li et al.2014Asian440791254626311922174041178483084350.50Erdogan et al.2011Caucasian5030415972716283261680.70Jeedigunta et al.2010Asian247254253241601335430620281144290.32Tanriover et al.2010Caucasian5050485253875446123080.14Harsløf et al.2010Caucasian228225134322199611316428630104910.97Musumeci et al.2009Caucasian100200130703560515524513129580.26Pérez et al.2008Caucasian64684880930254690536270.13Ivanova et al.2007Caucasian220180256184731103716319725113420.58Huang et al.2006Asian66116191132154946186438740.74Nam et al.2005Asian6168012006632736511110.96Qin et al.2004Asian2442731203681198135137409131111490.18Aerssens et al.2000Caucasian1352399217814645717530332111960.99AuthorYearEthnicitySample SizeERα *Pvu*IIHWECaseControlCaseControlPpPPPpppPpPPPpppShang et al.2016Asian1982761562402810070386166138110280.38Wang et al.2015Asian60603090324333288326310.40Li et al.2014Asian440791368512652381374981084693603620.12Sonoda et al.2012Asian1141711181102470201372053175650.26Erdogan et al.2011Caucasian50304258826163822101820.11Jeedigunta et al.2010Asian247254181313508111623227660112820.08Tanriover et al.2010Caucasian505039617251848521420160.79Harsløf et al.2010Caucasian228224198258461067623321563107540.52Musumeci et al.2009Caucasian1002001208030601018621431124450.53Pérez et al.2008Caucasian6468567211341958781234220.86Ivanova et al.2007Caucasian220180226214581105214821221106530.37Morón et al.2006Caucasian8717579951745251711794581490.33Huang et al.2006Asian661167953233310681641146590.64Nam et al.2005Asian61682101051302062580630.96Qin et al.2004Asian244273193295401139122332343137930.52Aerssens et al.2000Caucasian13523912015027664221925947125670.41AuthorYearEthnicitySample SizeERα G2014AHWECaseControlCaseControlAGAAGAGGAGAAGAGGWajanavisit et al.2015Asian991139410433283817947723560.53Gómez et al.2007Caucasian705003011022642303697402232370.21Ongphiphadhanakul et al.2003Asian33325234351315129521131032090.94Ongphiphadhanakul et al.2001Asian106122561568405837207233870.57AuthorYearEthnicitySample SizeERβ *Alu*IHWECaseControlCaseControlAGAAGAGGAGAAGAGGShoukry et al.2015Caucasian2001802231777573521252353065850.46Huang et al.2015Asian413890678148285108201384396541302470.57Harsløf et al.2010Caucasian2282241543022610210018626235116730.32Morón et al.2006Caucasian88177761001154231462083478650.23AuthorYearEthnicitySample SizeERβ *Rsa*IHWECaseControlCaseControlAGAAGAGGAGAAGAGGShoukry et al.2015Caucasian20018052348248150373231351440.47Huang et al.2015Asian413777329497632031477597951694211870.28Table 2Characteristics of included studies of lumbar spine BMD, femoral neck BMD, lumbar spine Z value and femoral neck Z value in ERα *Xba*I genotypesERα *Xba*ILumbar Spine BMD (g/cm^2^)ERα *Xba*IFemoral Neck BMD (g/cm^2^)XXXxxxXXXxxxAuthorYearEthnicityNMean ± SDNMean ± SDNMean ± SDAuthorYearEthnicityNMean ± SDNMean ± SDNMean ± SDIvanova et al.2007Caucasian730.75 ± 0.171100.81 ± 0.06370.87 ± 0.07Ivanova et al.2007Caucasian730.69 ± 0.081100.69 ± 0.04370.65 ± 0.03Albagha et al.2001Caucasian270.88 ± 0.03890.88 ± 0.02900.85 ± 0.02Albagha et al.2001Caucasian270.77 ± 0.03890.73 ± 0.01900.72 ± 0.02Aerssens et al.2000Caucasian140.94 ± 0.21640.93 ± 0.22570.88 ± 0.16Aerssens et al.2000Caucasian140.73 ± 0.03640.68 ± 0.09570.70 ± 0.20Jeedigunta et al.2010Asian600.89 ± 0.151330.86 ± 0.13540.64 ± 0.16Kurt et al.2012Caucasian410.79 ± 0.09940.8 ± 0.08400.83 ± 0.10Kurt et al.2012Caucasian410.95 ± 0.12940.92 ± 0.12400.93 ± 0.10Ge et al.2006Asian370.70 ± 0.101340.68 ± 0.07260.67 ± 0.07Kurabayashi et al.1999Asian11.18 ± 0.00200.92 ± 0.04610.92 ± 0.02Pérez et al.2008Caucasian70.59 ± 0.02360.58 ± 0.01200.56 ± 0.02Ge et al.2006Asian370.73 ± 0.081340.74 ± 0.09260.75 ± 0.13Pérez et al.2008Caucasian70.70 ± 0.02310.67 ± 0.02240.66 ± 0.02ERα *Xba*ILumbar Spine Z valueERα *Xba*IFemoral Neck Z valueXXXxxxXXXxxxAuthorYearEthnicityNMean ± SDNMean ± SDNMean ± SDAuthorYearEthnicityNMean ± SDNMean ± SDNMean ± SDShang et al.2016Asian146−1.98 ± 0.91146−1.65 ± 0.026−0.35 ± 2.19Ivanova et al.2007Caucasian73−2.00 ± 0.00110−2.00 ± 0.0037−1.90 ± 0.00Ivanova et al.2007Caucasian73−2.10 ± 0.00110−0.6 ± 0.0037−0.1 ± 0.00Albagha et al.2001Caucasian27−2.00 ± 0.2389−0.42 ± 0.1090−0.52 ± 0.12Albagha et al.2001Caucasian27−0.34 ± 0.2089−0.29 ± 0.1190−0.47 ± 0.11An et al.2000Asian100.42 ± 0.57840.11 ± 0.66152−0.32 ± 0.76An et al.2000Asian100.48 ± 0.49840.12 ± 0.85152−0.26 ± 0.58Table 3Characteristics of included studies of lumbar spine BMD, femoral neck BMD, lumbar spine Z value and femoral neck Z value in ERα *Pvu*II genotypesERα *Pvu*IILumbar Spine BMD (g/cm^2^)ERα *Pvu*IIFemoral Neck BMD (g/cm^2^)PPPpppPPPpppAuthorYearEthnicityNMean ± SDNMean ± SDNMean ± SDAuthorYearEthnicityNMean ± SDNMean ± SDNMean ± SDIvanova et al.2007Caucasian580.70 ± 0.091100.71 ± 0.10520.77 ± 0.06Ivanova et al.2007Caucasian580.52 ± 0.021100.68 ± 0.01520.76 ± 0.05Albagha et al.2001Caucasian370.87 ± 0.031020.86 ± 0.02670.88 ± 0.02Albagha et al.2001Caucasian370.75 ± 0.021020.71 ± 0.01670.75 ± 0.02Aerssens et al.2000Caucasian270.93 ± 0.18660.91 ± 0.22420.89 ± 0.17Aerssens et al.2000Caucasian270.69 ± 0.06660.70 ± 0.09420.69 ± 0.11Jeedigunta et al.2010Asian500.92 ± 0.18810.89 ± 0.111160.81 ± 0.14Kurt et al.2012Caucasian440.77 ± 0.081040.81 ± 0.09460.82 ± 0.09Kurt et al.2012Caucasian440.93 ± 0.131040.93 ± 0.11460.93 ± 0.09Ge et al.2006Asian380.68 ± 0.09930.67 ± 0.07670.69 ± 0.08Kurabayashi et al.1999Asian190.99 ± 0.04270.89 ± 0.03360.91 ± 0.02Ge et al.2006Asian380.68 ± 0.09920.67 ± 0.08670.69 ± 0.08Ge et al.2006Asian380.73 ± 0.10930.74 ± 0.09670.75 ± 0.10Qin et al.2004Asian400.57 ± 0.011130.60 ± 0.01910.59 ± 0.01Ge et al.2006Asian380.73 ± 0.10920.74 ± 0.09670.75 ± 0.10Pérez et al.2008Caucasian90.59 ± 0.01370.57 ± 0.01160.57 ± 0.02Qin et al.2004Asian400.70 ± 0.011130.70 ± 0.01910.72 ± 0.01Pérez et al.2008Caucasian110.73 ± 0.03340.66 ± 0.02170.65 ± 0.02ERα *Pvu*IILumbar Spine Z valueERα *Pvu*IIFemoral Neck Z valuePPPpppPPPpppAuthorYearEthnicityNMean ± SDNMean ± SDNMean ± SDAuthorYearEthnicityNMean ± SDNMean ± SDNMean ± SDShang et al.2016Asian28−1.54 ± 0.35100−1.67 ± 0.9170−2.79 ± 1.46Ivanova et al.2007Caucasian58−2.00 ± 0.00110−1.90 ± 0.0052−0.70 ± 0.00Ivanova et al.2007Caucasian58−2.40 ± 0.00110−2.10 ± 0.0052−1.50 ± 0.00Albagha et al.2001Caucasian37−0.29 ± 0.17102−0.59 ± 0.0967−0.28 ± 0.15Albagha et al.2001Caucasian37−0.35 ± 0.16102−0.44 ± 0.1067−0.28 ± 0.14An et al.2000Asian53−0.48 ± 0.90128−0.19 ± 0.801280.31 ± 0.49An et al.2000Asian53−0.53 ± 0.16128−0.21 ± 0.99650.22 ± 0.46

Power analysis {#Sec9}
--------------

Before initiation of the meta-analysis, a power analysis was conducted by using the Power and Precision V4 software to verify whether the included studies could offer adequate power (\> 80%). The result showed that the statistical power in our study was sufficient to detect the associations between ER gene polymorphisms and PMOP risk.

Associations between ER gene polymorphisms and PMOP risk {#Sec10}
--------------------------------------------------------

Overall, we did not find any significant association between ERα *Xba*I and ERα *Pvu*II polymorphisms and risk of PMOP in either overall, Caucasian or Asian populations (all *P* \> 0.05) (Table [4](#Tab4){ref-type="table"}). ERα G2014A polymorphism played a protcetive role in developing PMOP in Caucasian populations, while no significant association was observed in overall and Asian populations (both *P* \> 0.05). All the data are shown in Table [4](#Tab4){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}.Table 4Results of genetic models for ERα *Xba*I, ERα *Pvu*II, ERα G2014A, ERβ *Alu*I and ERβ *Rsa*I polymorphisms and osteoporosis susceptibility in postmenopausal womenComparisonNTest of associationModelTest of heterogeneityBegg's testEgger's testOR95% CI*P* value*P* valueI^2^ (%)*P* value*P* valueERα *Xba*IOverall14 X vs. x1.210.73--2.000.455R\< 0.00196.40.5840.955 XX vs. xx1.840.71--4.750.206R\< 0.00193.70.4430.465 Xx vs. xx1.190.83--1.700.357R\< 0.00180.10.5110.610 Xx/XX vs. xx1.340.82--2.180.240R\< 0.00190.40.6610.545 XX vs. Xx/xx1.500.70--3.240.296R\< 0.00193.40.4430.875Caucasian7 X vs. x1.150.76--1.740.510R\< 0.00188.0 XX vs. xx1.560.56--4.390.399R\< 0.00188.9 Xx vs. xx1.130.76--1.670.540R0.02159.8 Xx/XX vs. xx1.240.76--2.010.387R\< 0.00176.2 XX vs. Xx/xx1.300.56--3.030.536R\< 0.00188.2Asian7 X vs. x1.230.47--3.250.668R\< 0.00198.0 XX vs. xx2.180.37--12.730.388R\< 0.00198.1 Xx vs. xx1.220.63--2.360.553R\< 0.00188.0 Xx/XX vs. xx1.390.56--3.460.481R\< 0.00194.6 XX vs. Xx/xx1.770.44--7.140.424R\< 0.00196.0ERα *Pvu*IIOverall16 P vs. p0.960.71--1.290.769R\< 0.00192.30.7530.616 PP vs. pp0.990.55--1.780.961R\< 0.00190.81.0000.886 Pp vs. pp1.010.72--1.410.956R\< 0.00182.30.7530.501 PP/Pp vs. pp0.970.65--1.430.868R\< 0.00188.70.8930.539 PP vs. Pp/pp0.990.65--1.530.977R\< 0.00187.30.8930.976Caucasian8 P vs. p0.950.71--1.260.716R\< 0.00179.2 PP vs. pp0.930.49--1.790.831R\< 0.00181.4 Pp vs. pp0.980.73--1.310.877R0.11240.0 PP/Pp vs. pp0.970.67--1.390.861R0.00863.5 PP vs. Pp/pp0.970.59--1.580.895R\< 0.00178.2Asian8 P vs. p0.970.57--1.660.919R\< 0.00195.6 PP vs. pp1.080.40--2.960.877R\< 0.00194.4 Pp vs. pp1.040.58--1.880.889R\< 0.00190.2 PP/Pp vs. pp0.980.50--1.950.962R\< 0.00193.8 PP vs. Pp/pp1.050.50--2.200.891R\< 0.00191.8 ERα G2014AOverall4 A vs. G0.890.32--2.510.825R\< 0.00195.10.3080.237 AA vs. GG0.880.08--9.190.912R\< 0.00192.90.7340.419 GA vs. GG0.760.28--2.030.581R\< 0.00188.10.7340.530 GA/AA vs. GG0.730.22--2.410.601R\< 0.00192.80.7340.530 AA vs. GA/GG1.130.23--5.720.878R\< 0.00188.60.7340.299Caucasian1 A vs. G0.630.41--0.960.032R---- AA vs. GG0.280.07--1.210.089R---- GA vs. GG0.660.39--1.110.116R---- GA/AA vs. GG0.600.36--1.000.050R---- AA vs. GA/GG0.340.08--1.430.141R----Asian3 A vs. G1.000.23--4.460.996R\< 0.00196.6 AA vs. GG1.280.05--30.100.878R\< 0.00195.2 GA vs. GG0.770.17--3.450.736R\< 0.00191.3 GA/AA vs. GG0.760.12--4.620.765R\< 0.00194.8 AA vs. GA/GG1.690.20--14.270.630R\< 0.00192.2ERβ *Alu*IOverall4 A vs. G1.250.78--2.000.362R\< 0.00191.51.0000.997 AA vs. GG1.270.52--3.130.597R\< 0.00188.40.7340.647 GA vs. GG1.160.65--2.070.606R0.00181.00.7340.408 GA/AA vs. GG1.290.66--2.530.459R\< 0.00187.80.7340.612 AA vs. GA/GG1.210.65--2.240.553R\< 0.00185.70.4970.646Caucasian3 A vs. G1.230.58--2.570.590R\< 0.00194.3 AA vs. GG1.280.34--4.840.717R\< 0.00192.2 GA vs. GG1.300.60--2.780.504R0.00186.5 GA/AA vs. GG1.360.55--3.390.507R\< 0.00191.8 AA vs. GA/GG1.100.37--3.220.863R\< 0.00190.3Asian1 A vs. G1.311.06--1.620.012R---- AA vs. GG1.240.72--2.130.441R---- GA vs. GG0.840.48--1.480.548R---- GA/AA vs. GG1.100.64--1.870.739R---- AA vs. GA/GG1.441.12--1.840.004R----ERβ *Rsa*IOverall2 A vs. G0.920.50--1.700.785R0.01085.0 AA vs. GG0.490.34--0.70\< 0.001F0.26120.9 GA vs. GG0.870.41--1.840.722R\< 0.00185.9 GA/AA vs. GG0.850.37--1.950.704R\< 0.00188.9 AA vs. GA/GG0.660.48--0.900.009F0.4080Caucasian1 A vs. G1.300.83--2.040.245R---- AA vs. GG1.920.17--21.410.596F---- GA vs. GG1.320.80--2.150.273R---- GA/AA vs. GG1.330.82--2.170.246R---- AA vs. GA/GG1.810.16--20.110.630F----Asian1 A vs. G0.690.58--0.82\< 0.001R---- AA vs. GG0.470.33--0.68\< 0.001F---- GA vs. GG0.610.47--0.81\< 0.001R---- GA/AA vs. GG0.570.44--0.74\< 0.001R---- AA vs. GA/GG0.650.47--0.890.007F----*R* Random effect model*F* Fixed effect modelFig. 2Forest plot describing the meta-analysis under the dominant model for the association between ERα G2014A polymorphism and the risk of PMOP (GA/AA vs. GG)

With regard to ERβ polymorphism, ERβ *Alu*I was significantly associated with the risk of developing PMOP in Asian postmenopausal women under the recessive model; however, we did not observe any significant association between ERβ *Alu*I and PMOP risk in overall and Caucasian populations (both *P* \> 0.05) (Table [4](#Tab4){ref-type="table"} and Fig. [3](#Fig3){ref-type="fig"}). Furthermore, we also found that there was a remarkable association between ERβ *Rsa*I polymorphism and decreased PMOP risk in overall and Asian populations (Table [4](#Tab4){ref-type="table"}).Fig. 3Forest plot describing the meta-analysis under the recessive model for the association between ERβ *Alu*I polymorphism and the risk of PMOP (AA vs. GA/GG)

Associations between ER gene polymorphisms and BMD in PMOP women {#Sec11}
----------------------------------------------------------------

### ERα *Xba*I and lumbar spine bone mineral density (BMD g/cm^2^ and BMD Z value) {#Sec12}

In our meta-analysis, no significant difference in lumbar spine BMD (g/cm^2^) was observed between PMOP women with ERα *Xba*I XX, ERα *Xba*I Xx and ERα *Xba*I xx genotype in either overall, Caucasian or Asian populations (all *P* \> 0.05) (Table [5](#Tab5){ref-type="table"}). The lumbar spine BMD Z value in Caucasian PMOP women carrying ERα *Xba*I XX genotype was greater than that in those carrying xx genotype, while no significant difference was observed in overall and Asian populations (both *P* \> 0.05). ERα *Xba*I Xx genotype was found to be significantly associated with high lumbar spine BMD Z value in either overall or Caucasian populations but not in Asian populations.Table 5Meta-analysis of differences of Lumbar Spine BMD, Femoral Neck BMD, Lumbar Spine Z value and Femoral Neck Z value between each genotype of ERα *Xba*I and ERα *Pvu*II polymorphismERα *Xba*IXX vs. xxXx vs. xxTest of differencesModelTest of heterogeneityTest of differencesModelTest of heterogeneityNWMD (95% CI)*P* value*P* valueI^2^ (%)NWMD (95% CI)*P* value*P* valueI^2^ (%)Lumbar Spine BMD (g/cm^2^) Overall80.03 (−0.02, 0.08)0.198R\< 0.00194.280.02 (− 0.00, 0.05)0.086R\< 0.00194.1 Caucasian50.00 (−0.04, 0.04)0.917R\< 0.00190.250.00 (−0.02, 0.02)0.862R\< 0.00191.1 Asian30.11 (−0.16, 0.38)0.414R\< 0.00197.830.07 (−0.07, 0.20)0.326R\< 0.00197.3Lumbar Spine Z value Overall30.22 (−0.40, 0.83)0.495R\< 0.00188.530.24 (0.00, 0.47)0.046R0.04168.6 Caucasian10.13 (0.05, 0.21)0.001R----10.18 (0.15, 0.21)\< 0.001R---- Asian2−0.28 (−2.58, 2.02)0.811R0.00985.22−0.23 (− 1.81, 1.36)0.780R0.06271.3Femoral Neck BMD (g/cm^2^) Overall60.03 (0.01, 0.05)0.003R0.00175.560.01 (−0.00, 0.03)0.057R\< 0.00184.7 Caucasian50.03 (0.01, 0.05)0.009R\< 0.00180.450.01 (−0.00, 0.03)0.094R\< 0.00187.7 Asian10.03 (−0.01, 0.08)0.110R----10.01 (−0.02, 0.04)0.350R----Femoral Neck Z value Overall2−0.38 (−2.56, 1.80)0.733R\< 0.00199.220.25 (−0.07, 0.58)0.130R0.00191.6 Caucasian1−1.48 (−1.57, −1.39)\< 0.001R----10.10 (0.07, 0.13)\< 0.001R---- Asian10.74 (0.37, 1.11)\< 0.001R----10.43 (0.24, 0.62)\< 0.001R----ERα *Pvu*IIPP vs. ppPp vs. ppTest of differencesModelTest of heterogeneityTest of differencesModelTest of heterogeneityNWMD (95% CI)*P* value*P* valueI^2^ (%)NWMD (95% CI)*P* value*P* valueI^2^ (%)Lumbar Spine BMD (g/cm^2^) Overall100.02 (− 0.01, 0.04)0.216R\< 0.00195.510−0.01 (− 0.02, − 0.00)0.036R\< 0.00184.0 Caucasian50.01 (−0.04, 0.06)0.793R\< 0.00195.55−0.02 (− 0.03, 0.00)0.106R\< 0.00184.9 Asian50.03 (−0.02, 0.08)0.288R\< 0.00196.25−0.00 (− 0.02, 0.02)0.912R\< 0.00186.4Lumbar Spine Z value Overall30.11 (−0.55, 0.78)0.742R\< 0.00198.730.13 (−0.40, 0.67)0.623R\< 0.00195.9 Caucasian1−0.07 (− 0.13, − 0.01)0.031R----1− 0.16 (− 0.20, − 0.12)\< 0.001R---- Asian20.24 (−1.72, 2.20)0.809R\< 0.00199.020.34 (−1.18, 1.85)0.665R\< 0.00197.9Femoral Neck BMD (g/cm^2^) Overall8−0.04 (− 0.09, 0.01)0.135R\< 0.00199.38−0.02 (− 0.04, 0.01)0.132R\< 0.00198.2 Caucasian5−0.06 (− 0.16, 0.05)0.295R\< 0.00199.65−0.03 (− 0.05, 0.00)0.054R\< 0.00195.2 Asian3−0.01 (− 0.02, − 0.01)\< 0.001R1.0000.003−0.00 (− 0.03, 0.02)0.768R0.00978.7Femoral Neck Z value Overall2−0.39 (−1.15, 0.37)0.315R\< 0.00197.02−0.39 (− 0.57, − 0.20)\< 0.001R0.02480.3 Caucasian1−0.01 (− 0.08, 0.05)0.718R----1−0.31 (− 0.35, − 0.27)\< 0.001R---- Asian1−0.79 (−1.05, − 0.53)\< 0.001R----1− 0.50 (− 0.66, − 0.34)\< 0.001R----*R* Random effect model*F* Fixed effect model

### ERα *Xba*I and femoral neck bone mineral density (BMD g/cm^2^ and BMD Z value) {#Sec13}

Our pooled analyses indicated that the ERα *Xba*I XX genotype was significantly associated with increased femoral neck BMD in overall and Caucasian populations. In contrast, ERα *Xba*I XX genotype did not play a key role in femoral neck BMD in Asian populations (Table [5](#Tab5){ref-type="table"} and Fig. [4](#Fig4){ref-type="fig"}). Interestingly, compared with PMOP women with xx genotype, XX genotype was significantly associated with decreased femoral neck Z value in Caucasians, and increased femoral neck Z value in Asians (Table [5](#Tab5){ref-type="table"}). However, no significant association was observed between XX genotype and the femoral neck Z value in overall populations. In addition, Caucasians and Asians carrying the ERα *Xba*I Xx genotype were at risk of a high femoral neck Z value, while no significant association was found in overall populations. We did not observe remarkable relationships between ERα *Xba*I Xx genotype and femoral neck BMD in either overall, Caucasian or Asian populations (all *P* \> 0.05). All data are shown in Table [5](#Tab5){ref-type="table"}.Fig. 4Forest plot showed that XX genotype of ERα *Xba*I was associated with increased femoral neck BMD compared with xx genotype

### ERα *Pvu*II and lumbar spine bone mineral density (BMD g/cm^2^ and BMD Z value) {#Sec14}

With regard to ERα *Pvu*II, the difference in the lumbar spine Z value between the PP and pp. genotypes was − 0.07 (95% CI = − 0.03 to − 0.01, *P* = 0.031) in Caucasian PMOP women; however, no significant difference was observed in overall and Asian populations. For the Pp versus pp. genotype, the difference in lumbar spine BMD was − 0.01 (95% CI = − 0.02 to − 0.00, *P* = 0.036) in overall populations, and the difference in the lumbar spine Z value was − 0.16 (95% CI = − 0.20 to − 0.12, *P* \< 0.001) in Caucasian populations; however, we did not find any significant difference in lumbar spine BMD in either Caucasians or Asians, and in the lumbar spine Z value in overall and Asian populations (Table [5](#Tab5){ref-type="table"} and Fig. [5](#Fig5){ref-type="fig"}). In addition, no significant difference in lumbar spine BMD was observed between PP and pp. genotypes (*P* \> 0.05) (Table [5](#Tab5){ref-type="table"}).Fig. 5Forest plot showed that Pp genotype of ERα *Pvu*II was associated with increased lumbar spine BMD compared with pp. genotype

### ERα *Pvu*II and femoral neck bone mineral density (BMD g/cm^2^ and BMD Z value) {#Sec15}

We further found that the ERα *Pvu*II PP genotype was associated with decreased femoral neck BMD and Z value compared with the pp. genotype in Asians, while no significant difference in femoral neck BMD and Z value was observed in either overall and Caucasian populations (both *P* \> 0.05) (Table [5](#Tab5){ref-type="table"}). Furthrmore, PMOP women carrying the Pp genotype were at risk of a low femoral neck Z value, which was found in overall, Caucasian and Asian populations. Our study showed that there was no significant difference in femoral neck BMD between PMOP women with the Pp genotype and those with the pp. genotype (*P* \> 0.05). All the data are shown in Table [5](#Tab5){ref-type="table"}.

Sensitivity analysis and publication bias {#Sec16}
-----------------------------------------

We performed a leave-one-out analysis to estimate the sensitivity of our study and found that omission of any single study did not affect the overall statistical significance, indicating that the results of our meta-analysis are stable. Therefore, we could conclude that our meta-analysis data are relatively stable and credible. To estimate the publication bias of our meta-analysis, the Begg's and Egger's test was performed (Table [4](#Tab4){ref-type="table"}), indicating that there was minimal evidence of publication bias. The shape of funnel plot was symmetrical, which also showed no publication bias in our study (Fig. [6](#Fig6){ref-type="fig"}).Fig. 6Funnel plot of the ERα *Pvu*II polymorphism and PMOP risk

Discussion {#Sec17}
==========

Associations between ERα gene polymorphisms and PMOP risk {#Sec18}
---------------------------------------------------------

ERα *Xba*I and ERα *Pvu*II are the two restriction fragment length polymorphisms of ERα gene located in Intron 1 \[[@CR14]\]. Many studies \[[@CR11]--[@CR25], [@CR32]\] have been performed to explore the relationships between ERα *Xba*I, ERα *Pvu*II and PMOP risk; however, these studies have yielded inconsistent data \[[@CR11]--[@CR25], [@CR32]\]. Overall, we did not observe any significant association between ERα *Xba*I and ERα *Pvu*II polymorphisms and PMOP risk in either overall, Caucasian or Asian populations. In our opinion, the inadequate sample size, different ethnicities, various genotyping techniques, the presence of admixture in the population, gene-environment interactions, differences in age and measurement errors of different investigators might be important factors contributing to these controversial results. ERα *Xba*I and ERα *Pvu*II have proven to play key roles in attainment and maintenance of peek bone mass during young adulthood, and it might be difficult to document their effects in a population of postmenopausal women \[[@CR24]\]. In addition, *Pvu*II and *Xba*I polymorphisms are located in a non-functional area of the ER gene \[[@CR20]\], which might also contribute to our polled results. With regard to ERα G2014A, it is located on the exon region of chromosome 6p25.1, and may contribute via the epigenetic level for the efficiency of translation or receptor protein expression \[[@CR26]\]. Our results showed that a significant association between ERα G2014A and PMOP risk was observed only in Caucasian populations but not in overall and Asian populations.

Associations between ERβ gene polymorphisms and PMOP risk {#Sec19}
---------------------------------------------------------

ERβ has been found to be more abundant than ERα in trabecular bone, and more potent than ERα in mediating estrogen-induced repression of TNF-α expression, which is considered an important contributor to PMOP \[[@CR30]\]. ERβ *Alu*I is one of the widely-studied ERβ gene polymorphisms, knowing that it could alter mRNA stability and protein levels, leading to reduced synthesis of ERβ \[[@CR30]\]. In our study, ERβ *Alu*I was found to be significantly associated with increased risk of PMOP in Asian populations, while no significant relationship was observed in overall and Caucasian populations. Thus, different genetic backgrounds, environmental effects and/or their internal interactions could explain the diverse results in various ethnicities. ERβ *Rsa*I is another important polymorphism of ERβ. Our subgroup analysis revealed a significant association between ERβ *Rsa*I and PMOP risk in overall populations, which is consistent with the studies of Shoukry et al. \[[@CR30]\], and Huang et al. \[[@CR31]\].

Associations between ERα *Xba*I and lumbar spine and femoral neck BMD {#Sec20}
---------------------------------------------------------------------

Our pooled results showed that there was no significant difference in lumbar spine BMD between PMOP women carrying XX, Xx and xx genotype in either overall, Caucasian or Asian populations. However, WANG et al. \[[@CR39]\] reported that the *Xba*I polymorphism was significantly associated with BMD of the lumbar spine, and XX had a protective effect in comparison with carriers of the x alleles, which is consistent with the report of Ioannidis et al. \[[@CR41]\]. Both WANG and Ioannidis included all types of osteoporotic patients, not only postmenopausal women, which might be the most important reason for the difference between our results and theirs. As mentioned above, ERα *Xba*I might not play a key role in attainment and maintenance of peek bone mass in postmenopausal women \[[@CR24]\], and therefore it could be easily understood why no significant association was observed between ERα *Xba*I and lumbar spine BMD. With regard to femoral neck BMD, our study indicated that the femoral neck BMD in PMOP women with XX genotype was significantly higher than that in women with xx genotype in overall and Caucasian populations, which highlights the theory that ERα gene is involved in the pathogenesis of PMOP. No significant difference of femoral neck BMD was observed between PMOP women with Xx and xx genotype in each subgroup. Although no significant association was observed between lumbar spine BMD and ERα *Xba*I, we found that the lumbar spine Z value in both PMOP women carrying XX and those carrying Xx genotype was significantly higher than that in Caucasians carrying xx genotype. We also observed that XX genotype was associated with a low femoral neck Z value in Caucasians and high femoral neck Z value in Asians. In addition, Caucasians and Asians carrying Xx genotype were at risk of a high femoral neck Z value. However, why ERα *Xba*I plays a contradictory role in BMD and Z value at the lumar spine and femoral neck, and the mechanisms by which it is associated with BMD and Z value remains unclear and needs further investigation.

Associations between ERα *Pvu*II and lumbar spine and femoral neck BMD {#Sec21}
----------------------------------------------------------------------

Although the molecular mechanism underlying the effect of ERα *Pvu*II on bone mass is poorly understood, it is believed that ERα *Pvu*II might play a key role in BMD as it is in linkage disequilibrium with the TA polymorphism in the ER promoter that is associated with altered gene transcription \[[@CR20]\]. Our pooled analysis indicated that PMOP women with the Pp genotype had lower lumbar spine BMD than those with the pp. genotype. We also found that there was no significant difference in lumbar spine BMD between women with the PP genotype and those with the pp. genotype, which is consistent with the meta-analysis of Wang et al. \[[@CR40]\]. Furthermore, we observed that the PP genotype was associated with decreased femoral neck BMD in Asians, while Pp might not play a key role in femoral neck BMD in all subgroups. Interestingly, WANG et al. \[[@CR39]\] reported that PP play a role in protecting the lumbar spine but on the other hand it might be a risk factor for the femoral neck fracture. Wang CL \[[@CR40]\] and WANG KJ \[[@CR39]\] conducted their meta-analyses on osteoporotic women during menopause while our study included osteoporotic women post menopause, which might be the most important reason for the difference between our study and theirs. In addition, both PP and Pp genotypes were significantly associated with low lumbar spine Z value in Caucasians, but not in overall and Asian populations, probably because of the different genetic backgrounds in various ethnicities and interactions between genetic and non-genetic factors. PMOP women with the PP and Pp genotypes had lower femoral neck Z value than those with the pp. genotype in overall, Caucasian and Asian populations.

Limitations {#Sec22}
-----------

Although we performed a comprehensive analysis of the association between ERα, ERβ gene polymorphisms and PMOP risk and BMD in postmenopausal women, there are some limitations that should be addressed. First, high heterogeneity was observed in some of our pooled results, which might have negative impact on our conclusions. Second, PMOP is a disease whose etiology might be involved in several confounding factors, and other confounding factors such as age, years since menopause and estrogen therapy might interact with each other and play a key role in the etiology and progression of PMOP. However, no data available could be used in all recruited studies to detect the interactions between these confounding factors in PMOP patients. We should take all these confounding factors into consideration in our study rather than studying them separately, which is also a limitation of our meta-analysis. Third, we failed to perform a pooled analysis to detect whether ERα G2014A, ERβ *Alu*I and ERβ *Rsa*I were correlated with BMD in postmenopausal women as no sufficient data could be collected and analyzed. Therefore, larger-scale and better-designed studies are necessary to determine the association between ERα/β gene polymorphisms and PMOP risk and BMD in postmenopausal women.

Conclusion {#Sec23}
==========

ERα/β gene polymorphisms were significantly associated with PMOP risk and BMD in postmenopausal women, but each ERα/β gene polymorphism may have a distinct effect on PMOP risk and BMD in Asian and Caucasian populations.
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